UK markets open in 3 hours 54 minutes
  • NIKKEI 225

    28,984.56
    -238.21 (-0.82%)
     
  • HANG SENG

    19,793.35
    -129.10 (-0.65%)
     
  • CRUDE OIL

    88.06
    -0.05 (-0.06%)
     
  • GOLD FUTURES

    1,779.40
    +2.70 (+0.15%)
     
  • DOW

    33,980.32
    -171.69 (-0.50%)
     
  • BTC-GBP

    19,464.13
    -549.43 (-2.75%)
     
  • CMC Crypto 200

    557.85
    -14.96 (-2.61%)
     
  • ^IXIC

    12,938.12
    -164.43 (-1.25%)
     
  • ^FTAS

    4,146.49
    -19.89 (-0.48%)
     

Labcorp First National Laboratory to Offer Monkeypox Test

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Expands Access to Communities Across the United States

BURLINGTON, N.C., July 06, 2022--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox. This effort is part of the Administration’s commitment to quickly increase monkeypox testing access and capacity in every community during the ongoing outbreak.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005395/en/

Photo courtesy of Labcorp

Labcorp is the first national laboratory to offer this polymerase chain reaction (PCR) test, which it verified for the CDC, and the first to launch a more automated assay option.

"Labcorp appreciates the opportunity to support the CDC in its efforts to keep the public safe and manage the monkeypox outbreak," said Dr. Brian Caveney, chief medical officer and President of Labcorp Diagnostics. "We will initially perform all monkeypox testing in our main North Carolina lab and have the capacity to expand to other locations nationwide should the need arise."

Labcorp will offer the testing at its largest laboratory in the United States and has the ability to accept specimens from its customers, as well as overflow from public laboratories, from across the U.S. using its significant transportation and logistics capabilities. Eventually, Labcorp will have the ability to increase capacity up to 10,000 tests per week, which will double the current capacity provided through CDC’s Laboratory Response Network (LRN). This development will facilitate increased testing by leveraging established relationships between Labcorp and the clinics, hospitals, and health care providers it serves. Labcorp will use electronic laboratory reporting (ELR) to report results to jurisdictions as outlined in the CDC reporting guidance.

The public will go to their health care provider for sample collection and to initiate the testing process; however, health care providers can order the orthopoxvirus test from Labcorp just as they normally would order other tests. This test is currently available on the Labcorp test menu.

CDC guidance is that anyone with a rash that looks like monkeypox should talk to their health care provider, even if they don’t think they had contact with someone who has monkeypox.

Health care providers can access information on Labcorp’s test at www.labcorp.com/monkeypox. The latest CDC information on monkeypox is available at www.cdc.gov/monkeypox.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005395/en/

Contacts

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting